Ana Flores, MD
Retina Specialist · Memphis, TNNPI 1346295565
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 346 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AbbVie at 30.0% of the total.
Across 346 payments — averaging $24.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Regeneron Healthcare Solutions, Inc.$1K
- Sun Pharmaceutical Industries Inc.$925
- Harrow Eye, LLC$558
- Apellis Pharmaceuticals, Inc.$442
- Kala Pharmaceuticals, Inc.$386
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,51499%
- Education$1101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 132 | $2,587 |
| Regeneron Healthcare Solutions, Inc. | 22 | $1,158 |
| Sun Pharmaceutical Industries Inc. | 44 | $925 |
| Harrow Eye, LLC | 17 | $558 |
| Apellis Pharmaceuticals, Inc. | 9 | $442 |
| Kala Pharmaceuticals, Inc. | 23 | $386 |
| Novartis | 14 | $356 |
| Bausch & Lomb Americas Inc. | 12 | $350 |
| Oyster Point Pharma, Inc. | 16 | $345 |
| Eyevance Pharmaceuticals LLC | 9 | $257 |
| Mallinckrodt Hospital Products Inc. | 5 | $192 |
| Genentech USA, Inc. | 8 | $180 |
| Shire North American Group Inc | 3 | $160 |
| Sight Sciences, Inc. | 5 | $149 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $123 |
| Thrombogenics, Inc. | 2 | $61 |
| Tarsus Pharmaceuticals, Inc. | 2 | $55 |
| Dompe US, Inc. | 2 | $54 |
| Spark Therapeutics, Inc. | 2 | $46 |
| Thea Pharma Inc. | 2 | $43 |
| Alcon | 2 | $42 |
| Aerie Pharmaceuticals, Inc. | 2 | $38 |
| Omeros Corporation | 1 | $28 |
| Amgen | 2 | $27 |
| Alimera Sciences, Inc. | 1 | $25 |
| Eyepoint US, Inc. | 1 | $21 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,624 in reported general payments places this provider in the 70th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 339 | $195,752 |
| RestasisCyclosporine | 80 | $106,426 |
| CombiganBrimonidine Tartrate/Timolol | 196 | $88,689 |
| XiidraLifitegrast | 35 | $51,644 |
| Alphagan PBrimonidine Tartrate | 123 | $49,737 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $20,470 |
| TyrvayaVarenicline Tartrate | 21 | $19,916 |
| VyzultaLatanoprostene Bunod | 36 | $17,790 |
| MieboPerfluorohexyloctane/Pf | 11 | $14,859 |
| Prednisolone Acetate | 147 | $8,634 |
| ProlensaBromfenac Sodium | 14 | $7,550 |
| Cyclosporine | 13 | $6,972 |
| Methazolamide | 23 | $6,380 |
| Timolol Maleate | 260 | $5,944 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 24 | $5,574 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,587 | $440,604738 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $350 | $84,29282 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $38 | $20,47028 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $345 | $19,91621 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $123 | $10,77727 claims |
| AlconSimbrinza | $42 | $5,57424 claims |
| NovartisIlevro | $356 | $5,25411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 58 retina specialist providers in Tennessee.
Other retina specialist in Memphis
- Steven WilliamsMemphis$3K
- John ElfervigMemphis$2K
- Andrew KraussMemphis$752
- Steve CharlesGermantown$5.8M
- Carl AwhNashville$1.3M
- Peter SonkinNashville$949K
- Brandon BusbeeNashville$566K
- Eric SchneiderNashville$134K
- David ReichsteinNashville$114K
- Akshay ThomasNashville$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.